Skip to content
Screener

Pre-Tax Income at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$64.3M+473%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$48.79M+120%
Mannkind logo
MannkindMNKD
-$19.14M-2,136%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.57M+205%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
-$3.1M-3.6%

Other financials

Income statement

See full
Revenue$243.6M+55.4%
Gross profit$220.0M+59.2%
Operating income$27.2M+34.9%
Net income$25.4M+42.6%
EPS (diluted)$0.30+30.4%

Balance sheet

See full
Cash & equivalents$175.7M-8.5%
Total debt$8.9M-8.9%
Total equity$654.1M+32.1%
Total assets$896.1M+35.5%

Cash flow

See full
Operating cash flow$47.2M+68.0%
CapEx$663.0K+302%
Free cash flow$46.5M+66.6%

Valuation

See full
Market cap$5.97B+146%
Enterprise value$5.8B+159%
P/E74×-432×
P/S7.1×+2.5×

Profitability

See full
Gross margin89.8%+3.9pp
Operating margin11.9%+11.1pp
Net margin9.6%+8.7pp
FCF margin21.7%+8.8pp

Returns & leverage

See full
Return on equity14%+13.0pp
Debt / equity0.0×
Current ratio3.9×+0.3×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-087545
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Total operating expenses216,406136,637401,405261,150
Income from operations27,19420,16056,46133,432
Other income, net3,9512,7177,3655,010
Income before income taxes31,14522,87763,82638,442
Provision for income taxes(5,713)(5,045)(15,802)(12,071)
Net income$25,432$17,832$48,024$26,371
Net income per share attributable to ordinary shareholders—basic$0.33$0.24$0.62$0.36
Net income per share attributable to ordinary shareholders—diluted$0.30$0.23$0.58$0.34

Item 1. Financial Statements (unaudited)

FAQ

What is Kiniksa Pharmaceuticals International, plc's pre-tax income?
Kiniksa Pharmaceuticals International, plc (KNSA) reported pre-tax income of $31.15M in Q2 2026.
How has Kiniksa Pharmaceuticals International, plc's pre-tax income changed year-over-year?
Kiniksa Pharmaceuticals International, plc's pre-tax income increased by 36.1% year-over-year, from $22.88M to $31.15M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's pre-tax income?
Over 3 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's pre-tax income has grown at a -17.2% compound annual growth rate (CAGR), from -$156.54M to $88.87M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Kiniksa Pharmaceuticals International, plc's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude